ArticleScientific reports2024

First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis.

Xueyan Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.